News

BioNTech SE (BNTX) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ...

BioNTech SE (BNTX) reports significant revenue growth and strategic advancements despite ongoing challenges in the COVID-19 ...

BioNTech's Q2 revenues double on higher COVID vaccine sales

German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million ...

BioNTech posts Q2 beat as revenue more than doubles

BioNTech (BNTX) stock gains as the company surpasses Q2 2025 forecasts with 103% YoY revenue growth, thanks mainly to Pfizer ...

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

BioNTech reaffirmed its fiscal year 2025 guidance of 1.7 billion-2.2 billion euros compared to the consensus of 2.05 billion ...

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

“In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by ...
InvestorsHub on MSN5d

BioNTech shares climb over 2% as Q2 revenue doubles, Bristol Myers partnership boosts outlook

BioNTech SE (NASDAQ:BNTX) saw its shares rise 2.45% in pre-market trading Monday following a strong second-quarter report ...
Stocktwits on MSN4d

BioNTech Gets Price Target Bumps From BofA, Clear Street After Strong Q2, Oncology Pipeline Push

BioNTech is back in Wall Street’s spotlight after posting better-than-expected second-quarter results and doubling down on ...

BioNTech (BNTX) Reports Increased Sales And Reduced Losses In Q2 2025

BioNTech (BNTX) recently reported significant improvements in its financial performance, with quarterly sales nearly doubling compared to the previous year and a substantial reduction in net losses.